Skoči na glavni sadržaj

Izvorni znanstveni članak

HBsAg SEROCONVERSION IN THE TREATMENT OF CHRONIC HEPATITIS B WITH PEGYLATED INTERFERON

Lejla Čalkić
Lejla Bajramović-Omeragić
Azra Husić-Selimović
Ibrahim Aličković


Puni tekst: hrvatski pdf 474 Kb

str. 0-0

preuzimanja: 1.771

citiraj


Sažetak

The ideal goal of antiviral therapy or cure of chronic hepatitis B is HBsAg clearance and HBsAg seroconversion.
According to modern guidelines of all Associations for liver diseases pegylated interferon alfa-2a and nucleos(t)ide
analogues (entecavir, tenofovir) are fi rst choice in the treatment of chronic hepatitis B. The aim of the study was to evaluate
the success of the treatment of patients with chronic hepatitis B who received pegylated interferon. At the end of ten year
period, HBV DNA <50 IU/ml and HBsAg seroconversion achieved 4 (4/55, 7.00%) patients. All were HBeAg negative.
Additionally, is presented the case of patients, who, after the treatment, had the shortest period of healing. Patient is a man,
aged 47 years, with the newly discovered HBeAg negative chronic hepatitis B and pronounced activity of serum aminotransferases.
He was treated with pegylated interferon alfa-2a, 180 μg once a week, for 48 weeks. After antiviral therapy,
the patient is HBV DNA negative, HBsAg negative and neat aminotransferases, and 12 months after completion of antiviral
therapy comes to HBsAg seroconversion. The degree of cure of chronic hepatitis B, unfortunately, has not been entirely
satisfactory, with the exception of the few individual cases

Ključne riječi

Hepatitis B, chronic – drug therapy, Interferon-alpha – administration and dosage, therapeutic use, Antiviral agents – therapeutic use, Hepatitis B surface antigens – blood, hepatitis B, E antigens – blood, DNA, viral – blood, Treatment outcome

Hrčak ID:

178444

URI

https://hrcak.srce.hr/178444

Podaci na drugim jezicima: hrvatski

Posjeta: 2.252 *